MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy.  The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.

The late-breaker oral presentation titled "Utility of LEVADEX™ in Situations Where Early Intervention Paradigm is Impractical" evaluates the efficacy of LEVADEX in treating acute migraine at different time points during an attack, as early as initial migraine onset and as late as eight hours after onset of a migraine attack. It will be presented by Stewart Tepper, M.D., Director of Research for the Center for Headache and Pain at the Cleveland Clinic, during the late-breaker session on Friday, June 25 from 3:30 to 4:00 pm PT.

The poster presentation titled "The Efficacy and Tolerability of LEVADEX™ (Orally Inhaled DHE) for the Treatment of Migraine in Subjects with Concomitant Asthma—A Subgroup Analysis" evaluates the safety and efficacy of LEVADEX in this subpopulation. It will be presented on Friday, June 25 from 12:30 – 1:30 pm PT.